Several next-generation FGFR-targeting agents are being developed to address on-target resistance that commonly emerges after earlier FGFR inhibitors: Tinengotinib has shown signals of efficacy in FGFR2 fusion-positive CCA after prior FGFR-directed therapy (phase I/II), and is being evaluated in dedicated phase II and phase III trials in the FGFR inhibitor-refractory setting.16 Here, FGFR2 is linked to cholangiocarcinoma.